Investor Event Turns Spotlight on Novel Brain Canc
Post# of 368
(Total Views: 253)
Posted On: 05/11/2022 4:24:50 PM
Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
- CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer
- CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier
- Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients
- The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there
- An April 14 Virtual Investor Spotlight Event provided investors with information on CNS’s efforts, and the Zoom webcast will remain viewable through July for interested parties
Investors interested in potentially getting on board with a biopharmaceutical company working to develop novel brain cancer solutions can learn about the unmet need for treating deadly glioblastoma (“GBM”) and the work CNS Pharmaceuticals (NASDAQ: CNSP) is putting into granting GBM patients new hope by reviewing a recent Virtual Investor Spotlight Event that will be viewable for the next few weeks.
The spotlight event (event can be accessed at https://nnw.fm/2nYt8, presented by corporate and private client services advisors at JTC IR showcases CNS’s novel anthracycline Berubicin, which appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system.
Neuro-oncologist opinion leader Samuel A. Goldlust, M.D., joined CNS Pharmaceuticals CEO John Climaco for the live Web event April 14, which was recorded for on-demand access through July (https://nnw.fm/kNuki ). Dr. Goldlust currently serves as the Pitkin Chair in Neuro-Oncology and the Medical Director of the Brain and Spine Institute at the John Theurer Cancer Center, and is an investigator in CNS’s global Berubicin study.
Berubicin was the drug candidate subject of a small-scale Phase 1 clinical trial in 2006 that evaluated Berubicin’s safety, which was notable because one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent 16 years. Nearly half of the trial’s patients experienced a statistically significant improvement in clinical benefit (https://nnw.fm/KrJBk ).
GBM patients in general have a median survival rate of only 14.6 months after diagnosis, which is evidence of the need for an effective treatment for the thus-far incurable cancer.
Anthracyclines like Berubicin are among the most powerful chemotherapy drugs and are effective against more types of cancer than any other class of chemotherapeutic agents, according to the company. They are designed to utilize natural processes to cause deoxyribonucleic acid (“DNA”) damage in targeted cancer cells by interfering with the action of cell-growth enzyme topoisomerase II.
The potentially pivotal global trial that is currently under way began recruiting and dosing patients in the United States with Berubicin in 21-day cycles last year, and governmental approvals in European countries are advancing efforts to begin recruitment there (https://nnw.fm/id4ho ). Ultimately, more than 200 adult patients will participate in the “adaptive, multicenter, open-label, randomized and controlled study.”
The company expects to report an interim analysis of its results early next year when 50 percent of the patients have reached the six-month point in their dosing regimen. Primary completion of the study is anticipated by October 2024, with final completion expected by February 2025 (https://nnw.fm/TXU6f ).
CNS is also in the process of developing a drug candidate labeled WP1244, which uses anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than chemotherapy agent daunorubicin in stopping tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity, according to the company, making WP1244 worth evaluating for treating brain cancers, as well as pancreatic and ovarian cancers and lymphomas.
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer
- CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier
- Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients
- The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there
- An April 14 Virtual Investor Spotlight Event provided investors with information on CNS’s efforts, and the Zoom webcast will remain viewable through July for interested parties
Investors interested in potentially getting on board with a biopharmaceutical company working to develop novel brain cancer solutions can learn about the unmet need for treating deadly glioblastoma (“GBM”) and the work CNS Pharmaceuticals (NASDAQ: CNSP) is putting into granting GBM patients new hope by reviewing a recent Virtual Investor Spotlight Event that will be viewable for the next few weeks.
The spotlight event (event can be accessed at https://nnw.fm/2nYt8, presented by corporate and private client services advisors at JTC IR showcases CNS’s novel anthracycline Berubicin, which appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system.
Neuro-oncologist opinion leader Samuel A. Goldlust, M.D., joined CNS Pharmaceuticals CEO John Climaco for the live Web event April 14, which was recorded for on-demand access through July (https://nnw.fm/kNuki ). Dr. Goldlust currently serves as the Pitkin Chair in Neuro-Oncology and the Medical Director of the Brain and Spine Institute at the John Theurer Cancer Center, and is an investigator in CNS’s global Berubicin study.
Berubicin was the drug candidate subject of a small-scale Phase 1 clinical trial in 2006 that evaluated Berubicin’s safety, which was notable because one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent 16 years. Nearly half of the trial’s patients experienced a statistically significant improvement in clinical benefit (https://nnw.fm/KrJBk ).
GBM patients in general have a median survival rate of only 14.6 months after diagnosis, which is evidence of the need for an effective treatment for the thus-far incurable cancer.
Anthracyclines like Berubicin are among the most powerful chemotherapy drugs and are effective against more types of cancer than any other class of chemotherapeutic agents, according to the company. They are designed to utilize natural processes to cause deoxyribonucleic acid (“DNA”) damage in targeted cancer cells by interfering with the action of cell-growth enzyme topoisomerase II.
The potentially pivotal global trial that is currently under way began recruiting and dosing patients in the United States with Berubicin in 21-day cycles last year, and governmental approvals in European countries are advancing efforts to begin recruitment there (https://nnw.fm/id4ho ). Ultimately, more than 200 adult patients will participate in the “adaptive, multicenter, open-label, randomized and controlled study.”
The company expects to report an interim analysis of its results early next year when 50 percent of the patients have reached the six-month point in their dosing regimen. Primary completion of the study is anticipated by October 2024, with final completion expected by February 2025 (https://nnw.fm/TXU6f ).
CNS is also in the process of developing a drug candidate labeled WP1244, which uses anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than chemotherapy agent daunorubicin in stopping tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity, according to the company, making WP1244 worth evaluating for treating brain cancers, as well as pancreatic and ovarian cancers and lymphomas.
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)